Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.83 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.83 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.83 |
| ▸ | TNKS | O95271 | 1/20 | 0.83 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.83 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.83 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.72 |
| ▸ | PARP1 | P09874 | 2/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30434552 | 1.00 | PARP10 (0.83) | PARP10PARP14PARP15TNKSTNKS2 | |
| Hydrochloric Acid SCHEMBL28772951 | 0.98 | PARP10 (0.80) | PARP10PARP14PARP15TNKSTNKS2 | |
| Methyl Alcohol SCHEMBL8784315 | 0.96 | PARP10 (0.77) | PARP10PARP14PARP15TNKSTNKS2 | |
| Formic Acid SCHEMBL30728616 | 0.93 | PARP10 (0.73) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL6631040 | 0.91 | PARP10 (1.00) | PARP10PARP14PARP15TNKSTNKS2 | |
| Diphenylether SCHEMBL3013964 | 0.88 | PARP10 (0.88) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL618677 | 0.87 | PARP10 (0.81) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL1718819 | 0.86 | PARP10 (0.71) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL27320423 | 0.86 | PARP10 (0.73) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL3650722 | 0.86 | PARP10 (0.78) | PARP10PARP14PARP15TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3037412-B1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2020-09-30 | — | — | EP | claimed |
| CN-105658625-B | Indole amide compounds as inhibitors of cellular necrosis | 株式会社LG化学 | 2019-05-03 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2855699-B1 | PROMOTERS AND TERMINATORS FOR USE IN EUKARYOTIC CELLS | EXXONMOBIL RES & ENG CO (US) | 2018-07-18 | — | — | EP | claimed |
| US-9868731-B2 | Indole amide compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2018-01-16 | — | — | US | claimed |
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-07 | — | — | US | claimed |
| EP-3037412-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | claimed |
| US-20140316107-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | UNIVERSITY OF SOUTH CAROLINA | 2014-10-23 | — | — | US | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| WO-2003053361-A2 | PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| EP-1301527-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2003-04-16 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | claimed |
| WO-2002008251-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| CN-1310621-A | Substituted anilide compounds and methods | SMITHKLINE BEECHAM CORP (US) | 2001-08-29 | — | — | CN | claimed |
| US-4435332-A | POSTEMERGENCE, PREEMERGENCE HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-03-06 | — | — | US | claimed |
| US-4263039-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-04-21 | — | — | US | claimed |
| US-4173464-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-11-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, TMPRSS15, TMPRSS11D | PARP10 1690/4885PARP14 2027/4885PARP15 1586/4885 |
| US-20140316107-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | CDK4, CDK2, CDK2AP2 | PARP10 1791/4885PARP14 1604/4885PARP15 1961/4885 |
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | PARP10 2576/4885PARP14 3360/4885PARP15 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.